Esperion Therapeutics Inc’s recently made public that its Chief Commercial Officer Warren Eric unloaded Company’s shares for reported $106.0 on Apr 17 ’25. In the deal valued at $0.98 per share,108 shares were sold. As a result of this transaction, Warren Eric now holds 370,218 shares worth roughly $0.43 million.
Then, Halladay Benjamin sold 8 shares, generating $8 in total proceeds. Upon selling the shares at $0.96, the Chief Financial Officer now owns 481,702 shares.
Before that, Halladay Benjamin bought 8 shares. Esperion Therapeutics Inc shares valued at $8 were divested by the Officer at a price of $0.96 per share.
Goldman initiated its Esperion Therapeutics Inc [ESPR] rating to a Neutral in a research note published on December 18, 2024; the price target was $4. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in mid December with a ‘”an Overweight”‘ rating. BofA Securities also remained covering ESPR and has decreased its forecast on June 20, 2024 with a “an Underperform” recommendation from previously “Neutral” rating. BofA Securities revised its rating on January 03, 2024. It rated ESPR as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ESPR
On Monday, Esperion Therapeutics Inc [NASDAQ:ESPR] saw its stock unchanged to $1.17. Over the last five days, the stock has lost -2.50%. Esperion Therapeutics Inc shares have fallen nearly -46.82% since the year began. Nevertheless, the stocks have fallen -59.52% over the past one year. While a 52-week high of $3.94 was reached on 01/14/25, a 52-week low of $0.69 was recorded on 05/15/25.
Levels Of Support And Resistance For ESPR Stock
The 24-hour chart illustrates a support level at 1.1400, which if violated will result in even more drops to 1.1100. On the upside, there is a resistance level at 1.2000. A further resistance level may holdings at 1.2300.
